-+ 0.00%
-+ 0.00%
-+ 0.00%
ACTINOGEN's key Alzheimer's disease trial showed clinical benefit in elderly patients with mild to moderate disease, good safety, and showed a trend of benefit in the general population.
Share
Listen to the news
ACTINOGEN's key Alzheimer's disease trial showed clinical benefit in elderly patients with mild to moderate disease, good safety, and showed a trend of benefit in the general population.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending